Crystal Research Associates, LLC, an independent equity research firm, announced today a partnership with OneMedPlace to broaden services and provide additional visibility to research clients via the integrated OneMedPlace platform.
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
S.E.A. Medical Systems, Inc. is developing solutions for making intravenous (IV) drug delivery safer for patients.
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Hepregen is focused on improving and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies.
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
OneMedPlace is gearing up for OneMedForum NY 2011, the company’s 2nd annual Trans-Atlantic Conference to be held June 23-24 , 2011 in New York City.
OneMedPlace has entered into a partnership with Marketwire, a full-service newswire and communications workflow solutions provider for public relations, investor relations and marketing communications professionals, to accomplish the company’s media outreach goals.
Follow OneMedPlace on Twitter to discover the latest happenings in the life sciences industry.
Copyright © 2025 | WordPress Theme by MH Themes